549 related articles for article (PubMed ID: 16374600)
21. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
22. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
[No Abstract] [Full Text] [Related]
23. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
[TBL] [Abstract][Full Text] [Related]
24. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder.
Abdolhosseinzadeh S; Sina M; Ahmadiani A; Asadi S; Shams J
J Clin Pharm Ther; 2019 Feb; 44(1):39-48. PubMed ID: 30315580
[TBL] [Abstract][Full Text] [Related]
25. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.
Sarris J; Oliver G; Camfield DA; Dean OM; Dowling N; Smith DJ; Murphy J; Menon R; Berk M; Blair-West S; Ng CH
CNS Drugs; 2015 Sep; 29(9):801-9. PubMed ID: 26374743
[TBL] [Abstract][Full Text] [Related]
26. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.
Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
Eur Neuropsychopharmacol; 2014 Mar; 24(3):375-80. PubMed ID: 24406025
[TBL] [Abstract][Full Text] [Related]
27. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Ringold AL; Elliott MA
J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
[TBL] [Abstract][Full Text] [Related]
28. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
[TBL] [Abstract][Full Text] [Related]
29. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
[TBL] [Abstract][Full Text] [Related]
30. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
Stein DJ; Bouwer C; Hawkridge S; Emsley RA
J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814
[TBL] [Abstract][Full Text] [Related]
31. Prazosin addition to fluvoxamine: A preclinical study and open clinical trial in OCD.
Feenstra MGP; Klompmakers A; Figee M; Fluitman S; Vulink N; Westenberg HGM; Denys D
Eur Neuropsychopharmacol; 2016 Feb; 26(2):310-319. PubMed ID: 26712326
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis.
Maiti R; Mishra A; Srinivasan A; Mishra BR
Acta Psychiatr Scand; 2023 Jul; 148(1):19-31. PubMed ID: 37177823
[TBL] [Abstract][Full Text] [Related]
33. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
[TBL] [Abstract][Full Text] [Related]
34. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
35. Memantine augmentation for refractory obsessive-compulsive disorder.
Pasquini M; Biondi M
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1173-5. PubMed ID: 16730870
[TBL] [Abstract][Full Text] [Related]
36. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Modarresi A; Sayyah M; Razooghi S; Eslami K; Javadi M; Kouti L
Pharmacopsychiatry; 2018 Nov; 51(6):263-269. PubMed ID: 29100251
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Mundo E; Bianchi L; Bellodi L
J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
[TBL] [Abstract][Full Text] [Related]
38. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
[TBL] [Abstract][Full Text] [Related]
39. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
Husted DS; Shapira NA; Murphy TK; Mann GD; Ward HE; Goodman WK
J Psychiatr Res; 2007; 41(3-4):332-7. PubMed ID: 16860338
[TBL] [Abstract][Full Text] [Related]
40. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
